Used in targeted cancer therapy to inhibit tumor angiogenesis by neutralizing vascular endothelial growth factor A (VEGFA). This prevents VEGFA from binding to its receptors on endothelial cells, thereby suppressing the formation of new blood vessels that supply nutrients and oxygen to tumors. Employed in treating various cancers including colorectal, lung, glioblastoma, renal cell, and cervical cancers, often in combination with chemotherapy. Also applied in managing certain eye disorders like wet age-related macular degeneration and diabetic retinopathy by reducing abnormal blood vessel growth in the retina. Serves as a reference standard in bioanalytical assays for development and quality control of biosimilars and other anti-angiogenic therapeutics.